As with all potent opioid analgesics, possible side effects when using NUMORPHAN (oxymorphone)
Central Nervous System
Drowsiness, sedation, lightheadedness, unusual tiredness or weakness, headache,
dysphoria, euphoria, miosis, diplopia, blurred vision, nervousness, restlessness,
confusion, mental clouding, trouble sleeping, paradoxical CNS stimulation, hallucinations,
Nausea, vomiting, dry mouth, constipation, biliary tract spasm, cramps or pain,
loss of appetite, paralytic ileus or toxic megacolon in patients with inflammatory
Hypotension, orthostatic hypotension particularly in ambulatory patients, tachycardia,
bradycardia, palpitations, flushing.
Respiratory depression, atelectasis, allergic bronchospastic reaction, allergic
laryngeal edema, allergic laryngospasm.
Ureteral spasm, urinary hesitancy or retention, antidiuretic effect.
Itching, sweating, injection site reaction, allergic reaction (such as skin
rash, hives, and/or itching, swelling of the face).
Drug Abuse And Dependence
NUMORPHAN (oxymorphone) is a Schedule II opioid and is subject to the Federal Controlled
NUMORPHAN (oxymorphone) , as with other opioid drugs, can produce tolerance, psychological
dependence, and physical dependence and has the potential for being abused.
The addiction potential of the drug appears to be about the same as for morphine.
Withdrawal symptoms may occur when opioids are abruptly discontinued after
prolonged use. Withdrawal symptoms may be characterized by some or all of the
following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, gooseflesh,
restless sleep, and mydriasis during the first 24 hours. These symptoms often
increase in severity and over the next 72 hours may be accompanied by increasing
irritability, anxiety, weakness, twitching, and spasms of muscles; kicking movements;
severe backaches; abdominal and leg pains; abdominal and muscle cramps; hot
and cold flashes; insomnia; nausea, anorexia, vomiting, intestinal spasm, diarrhea,
coryza, and repetitive sneezing; increase in body temperature, blood pressure,
respiratory rate and heart rate. Because of excessive loss of fluids through
sweating, vomiting and diarrhea, there is usually marked weight loss, dehydration,
ketosis, and disturbances in acid-base balance. Cardiovascular collapse can
occur. Without treatment most observable symptoms disappear in 5-14 days; however,
there appears to be a phase of secondary or chronic abstinence which may last
for 2-6 months characterized by decreasing insomnia, irritability, and muscular
aches. In addition, the patient may have miosis and a slight lowering of blood
pressure, pulse rate, and body temperature;respiratory centers exhibit a decreased
response to the stimulatory effects of carbon dioxide.
The dose of NUMORPHAN (oxymorphone) should be gradually reduced before discontinuation in
those patients who require treatment for physical dependence.
Infants born to mothers physically dependent on opioids will also be physically
dependent and may exhibit respiratory difficulties and withdrawal symptoms (see
PRECAUTIONS; Usage in Pregnancy).